{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:31Z","timestamp":1788415951382,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sentinel lymph node (SLN) mapping has increasingly replaced systematic lymphadenectomy in apparent uterine-confined endometrial cancer (EC). However, concerns persist regarding the risk of recurrence following nodal surgical de-escalation, particularly in patients with aggressive histologic subtypes. We aimed to evaluate the oncologic safety of SLN-based nodal de-escalation by analyzing recurrence patterns and recurrence-free survival in patients with apparent early-stage EC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multi-institutional study including women with apparent uterine-confined EC who underwent primary surgery including SLN mapping, with or without pelvic and\/or para-aortic lymphadenectomy. Patients were grouped according to nodal staging strategy: SLN-only, SLN plus pelvic lymphadenectomy (PLND), and SLN plus PLND plus para-aortic lymphadenectomy (PALND). The primary endpoints were progression-free survival (PFS) and patterns of recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 2123 patients from 15 centers in six countries. SLN-only staging was performed in 1,341 patients (63.2%), SLN+PLND in 483 (22.8%), and SLN+PLND+PALND in 299 (14.1%). With a median follow-up of 44.9 months (IQR\u00a019.1\u201373.4), 121 recurrences were observed (5.6%). No statistically significant differences in PFS were observed among nodal staging groups. On multivariable Cox analysis, SLN-only staging was not associated with inferior PFS compared with SLN+PLND (HR 1.12, p=0.61), and the addition of PALND did not confer a significant benefit. Endometrioid high-grade histology, non-endometrioid high-risk histotypes, deep myometrial invasion, and lymphovascular space invasion were independently associated with recurrence. Isolated nodal relapse was uncommon (14.9%) and similarly distributed across groups. Exploratory molecular analysis did not show statistically significant differences in PFS across molecular subgroups, although expected survival trends were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In apparent uterine-confined EC, no significant differences in recurrence or nodal relapse were observed across nodal staging strategies. These findings support the use of SLN mapping as an adequate staging approach within a biology-driven framework, although they should be interpreted in light of the retrospective design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1810138","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:41Z","timestamp":1788412481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncologic safety of sentinel lymph node\u2013based nodal de-escalation in apparent uterine-confined endometrial cancer: a multicenter international cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessandro","family":"Buda","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Michele and Pietro Ferrero Hospital","place":["Verduno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Capasso","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mauro","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Michele and Pietro Ferrero Hospital","place":["Verduno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Perrone","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mueller","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology, Inselspital University Hospital Berne Department of Gynaecology","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milan-Bicocca","place":["Milan, Italy"]},{"name":"Division of Gynecology, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Imboden","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology, Inselspital University Hospital Berne Department of Gynaecology","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Grassi","sequence":"additional","affiliation":[{"name":"Division of Gynecology, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Garcia-Pineda","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tripodi","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Michele and Pietro Ferrero Hospital","place":["Verduno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Taskin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Ankara University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[{"name":"Santa Maria Misericordia Hospital, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Raimondo","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Human Reproduction Physiopathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Andrea","family":"Capozzi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Papadia","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Ente Ospedaliero Cantonale, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana","place":["Lugano, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Siegenthaler","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology, Inselspital University Hospital Berne Department of Gynaecology","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jvan","family":"Casarin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u2018Filippo Del Ponte\u2019 Hospital, University of Insubria","place":["Varese, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cucinella","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori, Fondazione Pascale","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vizza","sequence":"additional","affiliation":[{"name":"Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Zapardiel","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[{"name":"Santa Maria Misericordia Hospital, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Taskiran","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Koc University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS","place":["Rome, Italy"]},{"name":"Dipartimento Scienze della Vita e Sanit\u00e0 Pubblica, Universit\u00e0 Cattolica del Sacro Cuore Facolt\u00e0 di Medicina e Chirurgia","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: a randomized clinical trial","volume":"100","author":"Benedetti Panici","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613792","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial)","volume":"376","author":"Rossi","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70070-5","article-title":"Detection rate and diagnostic accuracy of sentinel-node biopsy in early-stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)","volume":"12","author":"Ballester","year":"2011","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer: combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.008","article-title":"Substantial lymphovascular space invasion is a significant risk factor for recurrence in endometrial cancer: a pooled analysis of PORTEC trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072052","article-title":"The risk of recurrence in endometrial cancer patients with low-volume metastasis in the sentinel lymph nodes: a retrospective multi-institutional study","volume":"15","author":"Buda","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.021","article-title":"The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-005157","article-title":"Establishing guidelines for sentinel lymph node ultrastaging in endometrial cancer","volume":"34","author":"Chiang","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2018.02.021","article-title":"Lymph node staging update in the American Joint Committee on Cancer 8th edition cancer staging manual","volume":"150","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108731","article-title":"The impact of substantial lymphovascular space invasion on sentinel lymph node status and recurrence in endometrial cancer patients (SLYM-EC study)","volume":"50","author":"Buda","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109750","article-title":"SLYMEC II study: overall survival analysis of the impact of lymphovascular space invasion in apparent early-stage endometrioid endometrial cancer","volume":"51","author":"Mauro","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.11.009","article-title":"Lymphadenectomy for high-grade endometrial cancer: does it impact lymph node recurrence","volume":"48","author":"Swift","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e79","article-title":"Comparison of progression-free survival outcome of sentinel node biopsy without ultrastaging versus lymphadenectomy in endometrial cancer: a propensity-matched analysis","volume":"34","author":"Lee","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.09.033","article-title":"The impact on survival of two different staging strategies in apparent early-stage endometrial cancer","volume":"147","author":"Buda","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.11.002","article-title":"Multicenter study comparing oncologic outcomes after sentinel lymph node algorithm versus comprehensive lymphadenectomy in serous and clear cell endometrial carcinoma","volume":"156","author":"Schlappe","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.022","article-title":"Sentinel lymph node algorithm versus comprehensive lymphadenectomy in deeply invasive endometrioid endometrial carcinoma","volume":"151","author":"Schlappe","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108018","article-title":"Sentinel\u00a0node mapping in high-intermediate and high-risk endometrial cancer: 5-year oncologic outcomes","volume":"50","author":"Cuccu","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ygyno.2020.04.687","article-title":"The added value of sentinel node mapping in endometrial cancer","volume":"158","author":"Kogan","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.254","article-title":"Sentinel node mapping versus lymphadenectomy in endometrial cancer: a systematic review and meta-analysis","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.01.013","article-title":"Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer","volume":"144","author":"How","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.77152","article-title":"Prognostic significance of histological grade in low-risk endometrial cancer","volume":"19","author":"Bak","year":"2022","journal-title":"Int J Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000488112","article-title":"Risk factors for recurrence in low-risk endometrial cancer","volume":"41","author":"G\u00fcng\u00f6rd\u00fck","year":"2018","journal-title":"Oncol Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110385","article-title":"Prognostic significance of molecular classification in high-risk endometrial cancer undergoing sentinel lymph node mapping","volume":"51","author":"Mariano","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1671823","article-title":"Prognostic impact of low-volume nodal metastases in endometrial cancer: a systematic review of molecular subtypes","volume":"12","author":"Bassi","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005030","article-title":"SENECA study: staging endometrial cancer based on molecular classification","volume":"34","author":"Chac\u00f3n","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.12.014","article-title":"Added prognostic value of sentinel lymph node mapping in endometrial cancer according to molecular subgroups","volume":"193","author":"Siegenthaler","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001698","article-title":"Oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT trial)","volume":"30","author":"Grassi","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003378","article-title":"Sentinel lymph node mapping versus systematic lymphadenectomy in endometrial cancer (ALICE trial)","volume":"32","author":"Baiocchi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003029","article-title":"Sentinel node biopsy versus no retroperitoneal node dissection in apparent early-stage endometrial cancer (ENDO-3)","volume":"31","author":"Obermair","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"104547","DOI":"10.1016\/j.ijgc.2026.104547","article-title":"Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53)","author":"Akladios","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004671","article-title":"Machine\u00a0learning endometrial cancer risk prediction model integrating ESMO guidelines with tumor immune features","volume":"33","author":"Bruno","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00859","article-title":"Training, validating, and testing machine learning models for endometrial cancer\u00a0recurrence","volume":"9","author":"Gonzalez Bosquet","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1810138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:43Z","timestamp":1788412483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1810138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1810138"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1810138","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1810138"}}